A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients
A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients Presenting to the Emergency Department and to Evaluate Its Side Effect and Safety Profile When Used in This Clinical Situation.
Sponsor: Henry Ford Health System
A PHASE4 clinical study on Acute Asthma, this trial is terminated or withdrawn. The trial is conducted by Henry Ford Health System and has accumulated 11 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Sep 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Jun 2023 — Sep 2023 [monthly]
Terminated PHASE4
-
Apr 2023 — Jun 2023 [monthly]
Terminated PHASE4
▶ Show 6 earlier versions
-
Mar 2023 — Apr 2023 [monthly]
Terminated PHASE4
-
Jan 2023 — Mar 2023 [monthly]
Terminated PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE4
First recorded
Jan 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Henry Ford Health System
- Sumitomo Pharma America, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Detroit, United States